Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
Phone(650) 574-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.13 billion
Profitability
Miscellaneous
Employees10,000
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable
Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions
What is Gilead Sciences' stock symbol?
Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."
How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?
Gilead Sciences announced a quarterly dividend on Monday, February 4th. Shareholders of record on Friday, March 15th will be paid a dividend of $0.63 per share on Thursday, March 28th. This represents a $2.52 dividend on an annualized basis and a yield of 3.88%. The ex-dividend date of this dividend is Thursday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.57. View Gilead Sciences' Dividend History.
How were Gilead Sciences' earnings last quarter?
Gilead Sciences, Inc. (NASDAQ:GILD) released its quarterly earnings data on Monday, February, 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $1.70 by $0.26. The biopharmaceutical company had revenue of $5.80 billion for the quarter, compared to analysts' expectations of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The business's quarterly revenue was down 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.78 earnings per share. View Gilead Sciences' Earnings History.
When is Gilead Sciences' next earnings date?
What price target have analysts set for GILD?
19 equities research analysts have issued 12-month price objectives for Gilead Sciences' shares. Their predictions range from $68.00 to $95.00. On average, they anticipate Gilead Sciences' stock price to reach $82.0625 in the next twelve months. This suggests a possible upside of 26.3% from the stock's current price. View Analyst Price Targets for Gilead Sciences.
What is the consensus analysts' recommendation for Gilead Sciences?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 8 hold ratings, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gilead Sciences.
What are Wall Street analysts saying about Gilead Sciences stock?
Here are some recent quotes from research analysts about Gilead Sciences stock:
- 1. Mizuho analysts commented, "We spoke to GILD. The company was able to confirm the title and time, and it noted that yes, this this is the pivotal DISCOVER trial, but couldn’t say exactly what data we will get. The company also confirmed that it’s a late-breaker and also an oral presentation. Clinicaltrials.gov still shows an active" status, but GILD noted to us that in general (not necessarily specific to this particular Descovy entry) clincaltrials.gov results can be presented at a lag. We note that oral presentations typically need to be informative, can’t just be baseline data, etc … our best guess is we’re getting both efficacy and safety data." (2/26/2019)
- 2. According to Zacks Investment Research, "Gilead’s HCV franchise continues to witness slowdown across key markets including the United States. and Europe, reflecting lower sales of Harvoni and Sovaldi as a result of competitive and pricing pressure. The franchise saw a significant plunge in sales due to new competition and fewer patient starts. Also, the HIV franchise faces competition from the likes of Glaxo, among others. While the Kite acquisition surely looks positive given the potential in the CAR T space, the deal looks expensive given the price Gilead paid. Nevertheless, Gilead’s HIV franchise maintains momentum, driven by the continued uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy. The FDA approval of Biktarvy has further widened the portfolio. Biktarvy has also been approved in Europe. Shares have outperfomed the industry in the last six months." (1/23/2019)
- 3. Cantor Fitzgerald analysts commented, ": We are increasing our price target to $88 from $87 and reiterating our Overweight rating. Gilead beat top and bottom line consensus expectations as the Biktarvy launch remains strong in HIV. Our price target is higher by $1/share given revenue trends were slightly more robust than we projected. The company also increased its product revenue guidance to $20.8-21.3B from $20-21B. Product revenues were $5.45B and EPS were $1.84/share. Biktarvy beat expectations by ~$50M, as it reported revenues of $375M. GILD has also benefited from a generic Letairis not entering the market, and it doesn’t expect an entrant in 2018. We have updated our estimates for the quarter." (10/26/2018)
- 4. Needham & Company LLC analysts commented, "Gilead reported $5.09B 1Q18 total revenue, below our $5.52B and consensus $5.3B ests. Product sales were $5.00B, below our $5.41B est. Gilead continues to lose share to Abbvie in HCV. Trend is worrisome, although mgmt still guiding for market share stabilization mid-2018. HIV sales in 1Q18 also disappointed, reportedly driven by bigger than expected seasonal inventory draw-down and generic TDF. Growth in HIV (i.e. Biktarvy success) is critical. NASH program has not yet distinguished itself, awaiting data from selonsertib Phase 3 trials (1H19) and 48wk combination Phase 2 trials (2020). Yescarta and cell therapy programs are in early stages." (5/2/2018)
Has Gilead Sciences been receiving favorable news coverage?
News stories about GILD stock have trended somewhat positive on Monday, according to InfoTrie. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Gilead Sciences earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.
Are investors shorting Gilead Sciences?
Gilead Sciences saw a drop in short interest in the month of February. As of February 28th, there was short interest totalling 10,321,882 shares, a drop of 20.3% from the February 15th total of 12,951,902 shares. Based on an average daily volume of 6,311,173 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.8% of the shares of the company are sold short. View Gilead Sciences' Current Options Chain.
Who are some of Gilead Sciences' key competitors?
Some companies that are related to Gilead Sciences include CSL (CSL), Vertex Pharmaceuticals (VRTX), Shire (SHP), Incyte (INCY), Neurocrine Biosciences (NBIX), SAGE Therapeutics (SAGE), GALAPAGOS NV/S (GLPG), Cronos Group (CRON), ACADIA Pharmaceuticals (ACAD), Allogene Therapeutics (ALLO), BTG (BTG), MorphoSys (MOR), MorphoSys (MOR), Abcam (ABC) and Acceleron Pharma (XLRN).
What other stocks do shareholders of Gilead Sciences own?
Who are Gilead Sciences' key executives?
Gilead Sciences' management team includes the folowing people:
- Daniel O'Day, Chairman & Chief Executive Officer
- Robin L. Washington, CFO, Principal Accounting Officer & Executive VP
- John G. McHutchison, Chief Scientific Officer
- Brett A. Pletcher, Secretary, Chief Compliance Officer & Executive VP
- William A. Lee, Executive Vice President-Research
Who are Gilead Sciences' major shareholders?
Gilead Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.05%), Oregon Public Employees Retirement Fund (2.24%), Bank of New York Mellon Corp (2.21%), Northern Trust Corp (1.31%), Geode Capital Management LLC (1.30%) and FMR LLC (1.09%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.
Which major investors are selling Gilead Sciences stock?
GILD stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Amundi Pioneer Asset Management Inc., Bank of New York Mellon Corp, Canada Pension Plan Investment Board, State Treasurer State of Michigan, BB Biotech AG, First Manhattan Co. and Boston Partners. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, John C Martin and John Francis Cogan. View Insider Buying and Selling for Gilead Sciences.
Which major investors are buying Gilead Sciences stock?
GILD stock was purchased by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Norges Bank, BlackRock Inc., Two Sigma Advisers LP, Los Angeles Capital Management & Equity Research Inc., Geode Capital Management LLC, Bank of Nova Scotia and American Century Companies Inc.. View Insider Buying and Selling for Gilead Sciences.
How do I buy shares of Gilead Sciences?
Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Gilead Sciences' stock price today?
One share of GILD stock can currently be purchased for approximately $64.97.
How big of a company is Gilead Sciences?
Gilead Sciences has a market capitalization of $82.87 billion and generates $22.13 billion in revenue each year. The biopharmaceutical company earns $5.46 billion in net income (profit) each year or $6.15 on an earnings per share basis. Gilead Sciences employs 10,000 workers across the globe.
What is Gilead Sciences' official website?
How can I contact Gilead Sciences?
Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at (650) 574-3000 or via email at [email protected]
MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.
